IL1B and deep vein thrombosis: The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) revealed the potential implication of IL-1β in conditioning the clinical course of patients after an acute coronary syndrome, concluding that the IL-1β innate immunity pathway with canakinumab significantly reduced the recurrence of new cardiovascular events [75,76].